Blaze Bioscience, Inc.
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Holding
- Established
- 2010-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
6
Active:0
Completed:4
Trial Phases
2 Phases
Phase 1:4
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)β’ Click on a phase to view related trials
Phase 1
4 (80.0%)Phase 2
1 (20.0%)Expanded Access for BLZ-100 (Tozuleristide)
- First Posted Date
- 2020-04-13
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Blaze Bioscience Inc.
- Registration Number
- NCT04343274
Study of Tozuleristide and the Canvas Imaging System in Pediatric Subjects With CNS Tumors Undergoing Surgery
Phase 2
Completed
- Conditions
- Pediatric Central Nervous System Tumor
- Interventions
- Device: Canvas System
- First Posted Date
- 2018-07-06
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Blaze Bioscience Inc.
- Target Recruit Count
- 118
- Registration Number
- NCT03579602
- Locations
- πΊπΈ
Chlidren's Hospital Los Angeles, Los Angeles, California, United States
πΊπΈUniversity of California, San Francisco, San Francisco, California, United States
πΊπΈUniversity of Florida Shands Hospital, Gainesville, Florida, United States
Exploratory Study of Safety and ex Vivo Fluorescence of BLZ-100 in Adult Subjects With Solid Tumors Undergoing Surgery
- First Posted Date
- 2015-07-14
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- Blaze Bioscience Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT02496065
- Locations
- πΊπΈ
Overlake Medical Center, Bellevue, Washington, United States
πΊπΈUniversity of Washington Medical Center, Seattle, Washington, United States
Safety Study of BLZ-100 in Adult Subjects With Sarcoma Undergoing Surgery
- First Posted Date
- 2015-06-08
- Last Posted Date
- 2016-05-26
- Lead Sponsor
- Blaze Bioscience Inc.
- Registration Number
- NCT02464332
- Locations
- πΊπΈ
Cedars-Sinai Medical Center, Los Angeles, California, United States
Study of BLZ-100 in Pediatric Subjects With CNS Tumors
- First Posted Date
- 2015-06-04
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Blaze Bioscience Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT02462629
- Locations
- πΊπΈ
Seattle Children's, Seattle, Washington, United States
- Prev
- 1
- 2
- Next
News
No news found